

**PE/Fire™ 700 anti-mouse/human CD45R/B220**

**Catalog # / Size:** 1116395 / 25 µg  
1116400 / 100 µg

**Clone:** RA3-6B2

**Isotype:** Rat IgG2a, κ


**Immunogen:** Abelson murine leukemia virus-induced pre-B tumor cells

**Reactivity:** Human, Mouse, Other

**Preparation:** The antibody was purified by affinity chromatography and conjugated with PE/Fire™ 700 under optimal conditions.

**Formulation:** Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide

**Concentration:** 0.2 mg/mL



C57BL/6 mouse splenocytes were stained with CD3 APC and CD45R/B220 (clone RA3-6B2) PE/Fire™ 700 (left) or stained with CD3 APC only (right).

**Applications:**

**Applications:** Flow Cytometry

**Recommended Usage:** Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤ 0.06 µg per million cells in 100 µL volume. It is recommended that the reagent be titrated for optimal performance for each application.

\* PE/Fire™ 700 has a maximum excitation of 565 nm and a maximum emission of 695 nm.

**Application Notes:** Clone RA3-6B2 has been described to react with an epitope on the extracellular domain of the transmembrane CD45 glycoprotein which is dependent upon the expression of exon A and specific carbohydrate residues. Additional reported applications (for the relevant formats) include: immunoprecipitation<sup>1</sup>, *in vitro* and *in vivo* modulation of B cell responses<sup>2-4</sup>, and immunohistochemistry of acetone-fixed frozen sections and formalin-fixed paraffin-embedded sections<sup>5,6</sup>.

- Application References:**
1. Coffman RL. 1982. *Immunol. Rev.* 69:5. (IP)
  2. George A, *et al.* 1994. *J. Immunol.* 152:1014. (Activ)
  3. Asensi V, *et al.* 1989. *Immunology* 68:204. (Activ)
  4. Domiati-Saad R, *et al.* 1993. *J. Immunol.* 151:5936. (Activ)
  5. Hata H, *et al.* 2004. *J. Clin. Invest.* 114:582. (IHC)
  6. Monteith CE, *et al.* 1996. *Can. J. Vet. Res.* 60:193. (IHC)
  7. Shih FF, *et al.* 2006. *J. Immunol.* 176:3438. (FC)
  8. Chang C L-T, *et al.* 2007. *J. Immunol.* 178:6984.
  9. Fazilleau N, *et al.* 2007. *Nature Immunol.* 8:753.
  10. Lang GL, *et al.* 2008. *Blood* 111:2158. [PubMed](#)
  11. Charles N, *et al.* 2010. *Nat. Med.* 16:701. (FC) [PubMed](#)
  12. del Rio ML, *et al.* 2011. *Transpl. Int.* 24:501. (FC) [PubMed](#)
  13. Murakami R, *et al.* 2013. *PLoS One.* 8:73270. [PubMed](#)

**Description:** CD45R, also known as B220, is an isoform of CD45. It is a member of the protein tyrosine phosphatase (PTP) family with a molecular weight of approximately 180-240 kD. CD45R is expressed on B cells (at all developmental stages from pro-B cells through mature B cells), activated B cells, and subsets of T and NK cells. CD45R (B220) is also expressed on a subset of abnormal T cells involved in the pathogenesis of systemic autoimmunity in MRL-*Fas*<sup>lpr</sup> and MRL-*Fas*<sup>gld</sup> mice. It plays a critical role in TCR and BCR signaling. The primary ligands for CD45 are galectin-1, CD2, CD3, and CD4. CD45R is commonly used as a pan-B cell marker; however, CD19 may be more appropriate for B cell specificity.

**Antigen**  
**References:**

1. Barclay A, *et al.* 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Trowbridge IS, *et al.* 1993. *Annu. Rev. Immunol.* 12:85.
3. Kishihara K, *et al.* 1993. *Cell* 74:143.
4. Pulido R, *et al.* 1988. *J. Immunol.* 140:3851.